Welcome to our dedicated page for Gilead Sciences SEC filings (Ticker: GILD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Gilead Sciences filings document material events, operating results, governance matters and capital-structure disclosures for a Delaware biopharmaceutical company whose common stock trades as GILD on the Nasdaq Global Select Market. Form 8-K reports furnish quarterly and annual financial results, including GAAP and non-GAAP measures and reconciliations, and disclose completed acquisition activity affecting oncology pipeline assets.
Proxy and annual meeting filings record director elections, auditor ratification and shareholder voting outcomes. Other current reports cover executive and governance changes, Regulation FD disclosures, material agreements, and formal exhibits tied to Gilead’s virology and oncology business, including clinical or regulatory disclosure categories when they are part of the company’s public reporting.
Johanna Mercier has filed a Form 144 notice to sell 3,000 shares of common stock through Morgan Stanley Smith Barney on or about 01/15/2026 on the NASDAQ market. The planned sale has an aggregate market value of $372,930.00, and the issuer has 1,240,679,623 shares outstanding. The shares to be sold come from restricted stock and performance share awards acquired from the issuer in early 2024.
Over the past three months, Johanna Mercier has already sold 3,000 and 28,000 shares of common stock in separate transactions, with gross proceeds of $366,000.00 and $3,524,173.10, respectively. By signing the notice, the seller represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
An insider has filed a Rule 144 notice to sell 3,000 shares of common stock of the issuer through Morgan Stanley Smith Barney LLC, with an aggregate market value of $372,930.00. The filing notes that there were 1,240,679,623 shares outstanding of this class, providing context for the size of the planned sale.
The shares to be sold were acquired on 01/24/2023 as performance shares from the issuer, with 3,000 securities acquired and deemed fully paid as of that date. The notice indicates an approximate sale date of 01/15/2026 on the NASDAQ exchange.
In the past three months, the person for whose account the securities are to be sold, Andrew Dickinson, has already sold 3,000 common shares on 12/15/2025 for gross proceeds of $366,000.00 and 2,500 common shares on 11/17/2025 for gross proceeds of $313,075.00. By signing, the seller represents that they do not know of undisclosed material adverse information about the issuer’s operations.
Gilead Sciences disclosed that its Chief Financial Officer, Andrew D. Dickinson, sold 3,000 shares of the company’s common stock on December 15, 2025 at a price of $122 per share. Following this sale, he beneficially owns 153,503 shares, held directly. The transaction was made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.
Gilead Sciences, Inc. reported an insider stock sale by its Chief Commercial Officer, Johanna Mercier. On 12/15/2025, Mercier sold 3,000 shares of Gilead common stock at $122 per share in a sale transaction coded "S".
After this sale, she beneficially owns 106,221 shares directly. The report notes that the transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 20, 2025, which allows executives to schedule trades in advance.
Gilead Sciences CEO Daniel P. O'Day reported insider stock activity involving restricted stock units linked to Gilead Sciences, Inc. common stock. On 12/10/2025, 10,426 restricted stock units were converted into 10,426 shares of common stock, increasing his directly held shares before a related disposition.
On the same date, 4,931 shares of common stock were disposed of at a price of $ 121.34 per share. After these transactions, O'Day directly owned 576,698 shares of Gilead common stock and 88,070 restricted stock units. Each restricted stock unit represents the right to receive one share, and the units follow a four-year vesting schedule in which 25% vest on the first anniversary of the grant date and the remaining balance vests 6.25% quarterly until fully vested.
Gilead Sciences Chief Commercial Officer Johanna Mercier reported routine equity award activity involving restricted stock units and company shares. On 12/10/2025, 3,842 restricted stock units converted into an equal number of Gilead common shares. On the same date, 1,814 shares of common stock were disposed of in a transaction coded "F," indicating shares were withheld or used to cover tax obligations at a price of $121.34 per share.
After these transactions, Mercier directly beneficially owns 109,221 shares of Gilead common stock and 27,674 restricted stock units. Each restricted stock unit represents the contingent right to receive one share, and the units follow a four-year vesting schedule, with 25% vesting on the first anniversary of the grant date and the remaining units vesting 6.25% quarterly until fully vested.
Gilead Sciences reported a leadership change affecting its legal and corporate affairs functions. The company announced that Deborah H. Telman will no longer serve as Executive Vice President, Corporate Affairs and General Counsel as of December 5, 2025. Her employment with the company will end later in December. This transition means Gilead will need to adjust leadership responsibilities in a key oversight and governance role, which can influence how the company manages legal risk, regulatory matters and external corporate communications.
Gilead Sciences, Inc. (GILD) reported an insider transaction by its Chief Financial Officer. On 11/17/2025, the CFO sold 2,500 shares of Gilead common stock at a price of $125.23 per share in an open-market sale coded as an "S" transaction. After this sale, the reporting person beneficially owns 154,555 shares of Gilead common stock in direct ownership. The filing notes that this sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on August 29, 2024, which is designed to allow insiders to trade according to predetermined instructions.
Gilead Sciences, Inc. (GILD) reported insider activity by its Chief Commercial Officer, Johanna Mercier. On 11/17/2025, she exercised a non-qualified stock option to acquire 25,000 shares of common stock at an exercise price of $66.64 per share, increasing her direct holdings before any sales.
That same day, she reported open-market sales of 25,524 shares at a weighted-average price of $125.8251 and 2,476 shares at a weighted-average price of $126.2575, all under a Rule 10b5-1 trading plan adopted on February 20, 2025. After these transactions, she directly owned 107,193 shares of Gilead common stock and 73,110 non-qualified stock options.
Gilead Sciences (GILD) disclosed insider activity by its EVP, Corporate Affairs & GC, on 11/12/2025 pursuant to a Rule 10b5‑1 trading plan adopted on August 13, 2025. The officer exercised non‑qualified stock options and sold the resulting shares the same day.
Exercises were for 17,181 shares at $75.12, 35,965 shares at $60.75, and 500 shares at $60.75, followed by sales of equal amounts. Sale prices included $124 and weighted‑average prices of $122.302 and $122.904, with transaction ranges of $121.87–$122.83 and $122.88–$122.92. After these trades, 43,676 common shares were beneficially owned directly.